Our science
Two proprietary platforms — V-Body and Chemistry — enabling precise and efficient targeted delivery.
Unmet medical needs
Despite major advances in the treatment of serious diseases, over 30% of patients worldwide still lack effective therapeutic solutions, leaving millions without adequate care. Current treatments continue to face limitations in efficacy and safety due to limited tissue penetration, particularly for complex diseases resistant to conventional approaches.
The problem: Lipids and LNPs naturally accumulate in the liver
Today’s RNA delivery by LNP primarily reaches the liver. Every other organ remains out of reach, leaving most diseases undruggable with RNA therapeutics.
The solution: Reach every tissue and drug every cell
At Valerio Therapeutics, we are developing the next generation of precision-guided therapies to address these challenges in three key areas:
- Immuno-inflammatory and autoimmune diseases, affecting nearly 10% of the global population, or more than 800 million people. Conditions such as rheumatoid arthritis, lupus, and Crohn’s disease remain difficult to treat in a lasting way.
- Rare metabolic diseases impact more than 300 million patients worldwide, with over 7,000 identified rare diseases. More than 90% of these conditions have no approved treatment, leaving patients with extremely limited options.
- Solid tumors, which account for 90% of new cancer cases and cause over 10 million deaths per year. Many advanced cancers remain resistant to current therapies, including conventional immunotherapies.
Specific tissue delivery remains a major challenge that impacts both efficacy and safety
One of the most significant challenges in current targeted therapies is the effective and precise delivery of therapeutic molecules to deep-seated tissues. Conventional monoclonal antibodies and other large biologics often struggle with poor penetration, while small-molecule drugs can suffer from limited specificity and off-target toxicity.
To attempt to solve such issues, we engineer V-Body targeted LNPs to deliver RNA precisely to the muscle, kidney, heart, brain, and immune tissues, unlocking nucleic acid therapy beyond the liver, comprising three main elements:
Through cutting-edge technology platforms and a strong commitment to innovation, Valerio is pushing the boundaries of medicine to deliver more effective, precisely targeted, and durable therapeutic solutions to every tissue, every cell to treat every disease.
V-Body
Receptor binding fragments enabling specific targeting
Payload
LNPs could be loaded with varied payload structures e.g. siRNA and mRNA
LNP
LNP decorated with V-Body to guide the payload to the target tissue
Next-Generation Precision-Guided Therapeutics
Harnessing the power of our integrated and differentiated V-Body conjugate platform to unlock the boundaries of targeted delivery.
